OBJECTIVE: To describe changes in cancer incidence in people with HIV in Australia since the introduction of highly active antiretroviral therapy (HAART). DESIGN: Population-based, retrospective cohort study of people with HIV (n = 20 232) using data linkage between national registers of HIV/AIDS and cancer in 1982-2004. METHODS: Age-adjusted and sex-adjusted incidence rate ratios with 95% confidence intervals were calculated to compare site-specific cancer incidence during the early (1996-1999) and late (2000-2004) HAART periods with that prior to HAART (1982-1995). Five-year age-specific, sex-specific, calendar year-specific, and state-specific standardized incidence ratios with 95% confidence interval were also calculated for each period. RESULTS: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma declined significantly (Ptrend < 0.001). Incidence of Hodgkin lymphoma was significantly higher during the early-HAART period (incidence rate ratio 2.34, 95% confidence interval 1.19-4.63) but declined thereafter (Pdiff = 0.014). Incidence of anal cancer was unchanged (Ptrend = 0.451) and remained raised more than 30-fold. Incidence declined significantly for melanoma (Ptrend = 0.041) and prostate cancer (Ptrend = 0.026), and, during the late-HAART period, was lower than in the general population for both cancers. Incidence of colorectal cancer was consistently lower than in the general population. CONCLUSION: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma has continued to decline among people with HIV in Australia, though it remains very substantially elevated. Incidence of Hodgkin lymphoma may now also be declining. Incidence of anal cancer has remained stable, and it is now the third most common cancer in HIV-infected Australians. Reasons for the reduced incidence of colorectal and prostate cancer, and more recently of melanoma, are unclear.
OBJECTIVE: To describe changes in cancer incidence in people with HIV in Australia since the introduction of highly active antiretroviral therapy (HAART). DESIGN: Population-based, retrospective cohort study of people with HIV (n = 20 232) using data linkage between national registers of HIV/AIDS and cancer in 1982-2004. METHODS: Age-adjusted and sex-adjusted incidence rate ratios with 95% confidence intervals were calculated to compare site-specific cancer incidence during the early (1996-1999) and late (2000-2004) HAART periods with that prior to HAART (1982-1995). Five-year age-specific, sex-specific, calendar year-specific, and state-specific standardized incidence ratios with 95% confidence interval were also calculated for each period. RESULTS: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma declined significantly (Ptrend < 0.001). Incidence of Hodgkin lymphoma was significantly higher during the early-HAART period (incidence rate ratio 2.34, 95% confidence interval 1.19-4.63) but declined thereafter (Pdiff = 0.014). Incidence of anal cancer was unchanged (Ptrend = 0.451) and remained raised more than 30-fold. Incidence declined significantly for melanoma (Ptrend = 0.041) and prostate cancer (Ptrend = 0.026), and, during the late-HAART period, was lower than in the general population for both cancers. Incidence of colorectal cancer was consistently lower than in the general population. CONCLUSION: Incidence of Kaposi sarcoma and non-Hodgkin lymphoma has continued to decline among people with HIV in Australia, though it remains very substantially elevated. Incidence of Hodgkin lymphoma may now also be declining. Incidence of anal cancer has remained stable, and it is now the third most common cancer in HIV-infected Australians. Reasons for the reduced incidence of colorectal and prostate cancer, and more recently of melanoma, are unclear.
Authors: Robert J Biggar; Elaine S Jaffe; James J Goedert; Anil Chaturvedi; Ruth Pfeiffer; Eric A Engels Journal: Blood Date: 2006-08-17 Impact factor: 22.113
Authors: Andrew E Grulich; Yueming Li; Ann McDonald; Patricia K L Correll; Matthew G Law; John M Kaldor Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: Yueming Li; Matthew Law; Ann McDonald; Patty Correll; John M Kaldor; Andrew E Grulich Journal: Am J Epidemiol Date: 2002-01-15 Impact factor: 4.897
Authors: Claire M Vajdic; Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Jeremy R Chapman; Janaki Amin; Stephen P McDonald; Andrew E Grulich Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-07-21 Impact factor: 4.254
Authors: Pragna Patel; Debra L Hanson; Patrick S Sullivan; Richard M Novak; Anne C Moorman; Tony C Tong; Scott D Holmberg; John T Brooks Journal: Ann Intern Med Date: 2008-05-20 Impact factor: 25.391
Authors: Mark Bower; Martin Fisher; Teresa Hill; Iain Reeves; John Walsh; Chloe Orkin; Andrew N Phillips; Loveleen Bansi; Richard Gilson; Philippa Easterbrook; Margaret Johnson; Brian Gazzard; Clifford Leen; Deenan Pillay; Achim Schwenk; Jane Anderson; Kholoud Porter; Mark Gompels; Caroline A Sabin Journal: Haematologica Date: 2009-03-31 Impact factor: 9.941
Authors: Gary M Clifford; Martin Rickenbach; Mauro Lise; Luigino Dal Maso; Manuel Battegay; Julia Bohlius; Emmanuelle Boffi El Amari; Urs Karrer; Gernot Jundt; Andrea Bordoni; Silvia Ess; Silvia Franceschi Journal: Blood Date: 2009-03-31 Impact factor: 22.113
Authors: K Petoumenos; M T van Leuwen; C M Vajdic; I Woolley; J Chuah; D J Templeton; A E Grulich; M G Law Journal: HIV Med Date: 2012-08-30 Impact factor: 3.180